# 1. Financial Performance ## A. Key Figures * **EBITDA:** **₹31.12 Cr** FY26 (+62.59%) · **30.60%** Margin (+560 bps) * **PAT:** **₹20.12 Cr** FY26 (+79.42%) · **19.79%** Margin (+509 bps) * **Debt:** **Zero** Total Debt (Repaid ₹12 Cr) ## B. Revenue Growth * **Accelerated Momentum:** Delivered robust double-digit top-line growth for the full year, with H2 performance showing strong sequential and year-on-year gains. * **Service-Led Expansion:** Growth is increasingly underpinned by a strategic pivot toward hospital services, which command higher ticket sizes than traditional product sales. ## C. Margins & Profitability * **Structural Margin Uplift:** Significant expansion in operating margins driven by the shift to hospital services, which yield approximately **10% higher** margins than the product segment. * **Hospital Economics:** Management is targeting a **35% EBITDA** for the hospital sector, supported by lower marketing overheads and immediate operational breakeven for new facilities. * **Cost Structure:** Total employee costs sit at approximately **20%**, encompassing clinical staff who perform dual research and operational roles. ## D. Debt & Receivables * **Balance Sheet De-leveraging:** Achieved debt-free status following the utilization of IPO proceeds for full debt repayment, expected to further bolster net margins via reduced interest outflow. * **Working Capital:** Trade receivables rose to **₹20 Cr**, marking a notable increase over historical trends that warrants monitoring. ## E. Capital Allocation * **Asset-Light Expansion:** Low-intensity CapEx model with hospital beds costing **₹2 lakh to ₹3 lakh** each and day-care centers requiring **₹15 lakh to ₹20 lakh** for setup. * **Strategic Reinvestment:** IPO funds are earmarked for a major telemedicine scale-up, including the recruitment of a **500-person team** to drive digital reach. * **Self-Funded Growth:** High internal profitability has rendered capital expenditure for future expansion a secondary concern for management. --- # 2. Operating Segments & Capacity ## A. Key Figures * **Revenue Mix:** **53.8%** Services (vs 35% YoY) · **46.2%** Products (vs 64% YoY) * **Capacity:** **223-235** Current Beds · **500** FY26 Target · **2,000** 3-4 Year Target * **Utilization:** **69%** Overall Occupancy · **90%+** Mature Facilities · **35-40%** New Facilities * **Unit Economics:** **₹8,400** ARPOB · **₹2L - ₹3L** Capex per Bed ## B. Service vs Product Mix * **Strategic Pivot to Services:** The business has undergone a significant structural shift, with services now the primary revenue driver, displacing the previous product-heavy mix. * **Diversified Service Streams:** Revenue is stabilized through a triple-model approach: in-patient admissions, day-care Panchkarma, and OPD services/medicine sales. ## C. Hospital & Clinic Network * **Aggressive Footprint Expansion:** Management is scaling the physical network with a target of **30 new clinics** this fiscal year, despite the strategic closure of **4-5 underperforming units** during restructuring. * **Specialized Infrastructure:** The portfolio is anchored by a **100-bed NABH accredited** facility in Gurgaon, supported by a growing network of specialty centers in Delhi NCR and major metros. * **Service Growth Drivers:** Triple-digit H2 service revenue growth was catalyzed by new facility launches in Pithampura, Delhi, Gurgaon, and Jaipur. ## D. Bed Capacity Expansion * **Aggressive Scaling Targets:** The company aims to more than double its capacity to **500 beds** this year, having already secured a new **100-bed** hospital agreement in Gurgaon. * **Asset Optimization:** Growth will be supported by sweating existing assets, such as the Udaipur facility, which currently utilizes only **30%** of its **100-bed** potential. * **High-End Diversification:** A new **25-bed luxury facility** is slated for launch within **three months**, representing a move into higher-margin segments. ## E. Occupancy & ARPOB * **Capacity Constraints in Key Hubs:** Mature hospitals in Delhi and Gurgaon have reached **100% occupancy**, largely driven by high volumes of government-empanelled business. * **Insurance Tailwinds:** Margin stability and occupancy growth are being bolstered by the increasing inclusion of Ayurveda in insurance coverage and government empanelment. * **Operational Ramp-up:** Management anticipates a **three-year maturation cycle** for new facilities to reach peak occupancy as patient awareness and empanelments scale. --- # 3. Business Model & Strategy ## A. Key Figures * **Addressable Market:** **$43 Billion** Total Ayush market size * **Infrastructure Pipeline:** **500-seater** Telemedicine center (IPO objective) · **100** Super-specialty clinics (3-year target) * **Near-term Expansion:** **30** Clinics planned for the current year ## B. Integrated Telemedicine Funnel * **Ecosystem Integration:** The business model vertically integrates manufacturing with a multi-channel distribution funnel (telemedicine, clinics, and hospitals) to capture both preventive and active treatment segments. * **Proprietary Distribution:** Management is shifting away from external patient sources, focusing on an "Ayurveda in every household" strategy where products are sold exclusively through the company's own healthcare infrastructure. * **Digital Acquisition:** The new large-scale telemedicine center serves as the primary backend engine for patient acquisition, driving follow-ups and referrals into the physical hospital network. ## C. Standardized Medical Protocols * **Brand-Led Model:** The company utilizes a system-driven approach rather than a doctor-dependent one, employing strict SOPs and standardized protocols to ensure brand loyalty over individual practitioner preference. * **Specialized Infrastructure:** Management has rejected third-party collaborations or college-based facilities in favor of proprietary **super-specialty centers** to maintain high-quality, protocol-driven patient outcomes. * **Holistic Integration:** Clinical care combines traditional Ayurvedic principles with lifestyle education (yoga, meditation) to reduce customer acquisition costs through organic, outcome-based growth. ## D. Hub-and-Spoke Expansion * **De-risked Scaling:** To ensure **Day 1 breakeven**, the company follows a tiered "Telemedicine-to-Clinic-to-Hospital" progression, only upgrading facilities once a local patient base is firmly established. * **Geographic Density:** Expansion is focused on high-potential domestic metros (Delhi NCR, Mumbai, Bangalore) and under-represented regions like Chandigarh and Dehradun, while US/Europe markets are serviced via digital channels. * **Operational Independence:** The company is currently avoiding third-party corporate hospital tie-ups, prioritizing its own ecosystem to maximize revenue capture across new medical verticals and disease categories. ## E. Insurance & Corporate Empanelment * **Institutional Drivers:** Growth is being catalyzed by a pilot project with the **Ministry of Defense** (exclusive 3-year empanelment) and existing tie-ups with major corporates like **Hero Motors, Maruti, and Honda**. * **Cashless Transition:** A major push into the insurance segment is slated for **May 2026**, with ongoing negotiations with the **General Insurance Corporation (GIC)** to centralize cashless transactions. --- # 4. Product & R&D Portfolio ## A. Key Figures * **Product Pipeline:** **80** Approved Products · **300** Approved SKUs · **300** Products awaiting regulatory approval * **Infrastructure Expansion:** **30** New Super-specialty Clinics · **500-seat** Telemedicine Center · **25-bed** Luxury Hospital ## B. Manufacturing & SKUs * **Vertical Integration Strategy:** Management maintains a strictly in-house manufacturing ecosystem for all medicines to ensure efficacy and quality control, avoiding third-party sourcing. * **Portfolio Refresh:** Extensive labeling and packaging revamps are underway across the SKU library to support upcoming multi-format market launches. * **Wellness Diversification:** Strategic pivot into preventative healthcare via **FSSAI-approved** wellness products and a dedicated e-commerce platform to diversify revenue streams. ## C. Specialized Treatment Verticals * **Clinical Specialization:** Expansion into high-value "super-specialty" clinics focusing on **Panchakarma, IVF support, and Uttarbasti kriya** to address chronic and lifestyle diseases. * **Core Competencies:** Kidney-related ailments, arthritis, and liver disorders remain the primary volume and success drivers for the clinical business. * **Targeted Care Segments:** New clinical verticals are being established to capture demand in niche segments including fertility, obesity, and spinal health. ## D. Luxury Segment Development * **High-End Market Capture:** Development of luxury infrastructure in Delhi designed to cater to a premium patient demographic with a ticket size of **₹15,000 to ₹20,000** per day. * **Strategic Finalization:** Site selection for the luxury wellness hospital is complete, marking a shift toward high-margin, premium healthcare services. ## E. Research & Training * **R&D Centrality:** The strategic importance of R&D is signaled by the Head of R&D being the firm's highest-paid employee, bringing **18 years** of manufacturing expertise. * **Multifunctional Operations:** The R&D department serves as a core operational hub, managing **NABH accreditation**, internal doctor training, and therapist development. --- # 5. Customer & Marketing Metrics ## A. Key Figures * **Total Sales:** **₹102 Cr** FY25–26 * **Digital Reach:** **8 Lakh** Platform Subscribers · **800,000** YouTube Followers * **Ad Spend:** **13-14%** of Revenue * **Clinical Workforce:** **40+** Doctors (incl. **15 MDs**) · **71** Trained Therapists * **Clinic Revenue Contribution:** **50%** ## B. Digital Presence & Marketing Strategy * **Omnichannel Ecosystem:** Leveraging a D2C model and e-commerce platform to reach a global patient base, supported by active marketing on Google and Meta. * **Synergistic Sales Model:** Utilization of a cross-selling strategy to convert product buyers into service patients, optimizing the substantial digital following and call center data. * **Efficiency in Expansion:** Social media presence and existing lead data are being used to minimize costs associated with opening new physical locations. ## C. Patient Acquisition & Retention * **Organic Growth Engine:** Primary marketing strategy relies on organic referrals and repeat patients, focusing on measurable health outcomes rather than terminal care. * **Diversified Channels:** Patient inflow is secured through a mix of digital advertisements, corporate panels, insurance channels, and referrals. * **Luxury Segment Pivot:** Expansion into premium facilities leverages existing inquiries, requiring **zero additional lead-generation costs**. ## D. Workforce & Talent Scaling * **Aggressive Hiring:** Recent headcount growth includes **57 new hires** in the last quarter and **47 personnel** post-IPO to support telemedicine and hospital operations. * **Specialized R&D:** A dedicated team of **five MDs** in Dravyaguna and Rasashastra focuses exclusively on new product formulations. * **Standardized Training:** To ensure quality control, the company runs government-affiliated (Ayush) training programs to pipeline staff for hospitals and day care centers. --- # 6. Risks & Operational Factors ## A. Key Figures * **Government Receivables:** **₹8-9 Cr** Outstanding trade receivables * **Receivable Liquidity:** **2-3 Months** Expected cash conversion cycle for non-government dues ## B. Geographic Revenue Concentration * **Regional Dependency:** Historical filings reveal significant revenue concentration in **Delhi and Gurgaon units**, posing potential key-man risks despite a broader facility footprint. * **Strategic Diversification:** Management is counteracting regional concentration through a Pan-India expansion, maintaining active facilities in **six major cities** including Mumbai and Bangalore. * **International Footprint:** The company leverages a stable five-year operational history in the **United States and Europe** to diversify its revenue base. ## C. Working Capital & Inventory * **Receivable Outlook:** While government-related accounts remain pending per standard timelines, the majority of trade receivables are slated for near-term cash conversion. * **Inventory Efficiency:** Inventory days remain stable but are noted as **high relative to industry peers**, suggesting a potential area for operational optimization. ## D. Regulatory Compliance * **Clinical Standardization:** All facilities have successfully cleared **NABH audits** and transitioned into daycare centers to support specialized Ayurvedic treatment protocols. --- # 7. Guidance & Outlook ## A. Key Figures * Revenue Growth Target: 50% minimum YoY · Double revenue from products/services via new telemedicine setup * **Hospital Count:** **6** current ## B. Revenue Growth Targets * **Aggressive Scaling:** Management anticipates robust double-digit top-line expansion, fueled by team growth and a strategic pivot toward new clinics and hospitals. * **Self-Sustaining Model:** Growth trajectory is expected to be financed primarily through internal accruals, minimizing the need for significant external capital infusions. * **Infrastructure Leverage:** The transition to a new **500-seater setup** acts as a primary catalyst to significantly multiply current service and product volumes. ## C. Facility Expansion Roadmap * **Exponential Capacity Hike:** Plans are underway to increase bed capacity by nearly **7x to 9x** over the next 36 months to establish a national footprint. * **Digital Integration:** A new telemedicine facility is slated for launch within **12 to 18 months**, with financial contributions expected to materialize in the subsequent fiscal year. ## D. Margin Improvement & Reporting * **Profitability Drivers:** Margin expansion is expected to track alongside revenue scaling, supported by the launch of new verticals and optimized hospital utilization. * **Governance Milestone:** The company will transition to a **quarterly financial reporting** cycle effective **Q1**, enhancing transparency for the investor community post-listing.